Analysts on Wall Street project that Thermo Fisher Scientific (TMO) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year. Revenues are projected to reach $10.65 billion, increasing 1% from the same quarter last year.The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial pro ...

Key Takeaways TMO is set to report Q2 earnings on July 23, with revenues estimated at $10.65B and EPS at $5.22. Analytical Instruments revenues are projected to grow 3.3% to $1.84B, driven by new AI-enabled platforms. Life-Science Solutions may see 0.5% growth to $2.37B, aided by proteomics and cell therapy initiatives.Thermo Fisher Scientific Inc. (TMO) is slated to release second-quarter 2025 results on July 23, before market open.Thermo Fisher’s first-quarter earnings of $5.15 per share beat the Zacks ...

Group 1 - Royalty Pharma's board of directors has approved a dividend of $0.22 per Class A ordinary share for Q3 2025, to be paid on September 10, 2025, to shareholders of record by August 15, 2025 [1] Group 2 - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to leading global pharmaceutical companies [2] - The company has a portfolio of royalties linked to over 35 commercial products, including notable therapies such as Vertex's Trikafta, GSK's Trelegy, and Roche's Evrysdi, among others [2] - Royalty Pharma funds innovation both directly by co-funding late-stage clinical trials and indirectly by acquiring existing royalties from original innovators [2]

WEST PALM BEACH, FLORIDA, July 18, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary that is focused on the development of its epigenetics business Our Epigenetics subsidiary has been serving as a pioneer in the development and integration of epigenetic biomarkers into state-of-the-art underwriting protocols and consumer engagement tools and owns Pat ...

Core Viewpoint - AB Akola Group has temporarily postponed the construction of a biomethane gas production plant in the Kaišiadorys district, which is part of its long-term development strategy to address rising energy costs, excess biological waste, and climate impact reduction [1][2]. Investment and Financial Aspects - The biomethane power plant project is expected to process up to 140,000 tons of organic waste annually, generate 85 GWh of renewable energy, and reduce CO2 emissions by up to 29,000 tons per year, with an estimated payback period of less than 7.5 years [1]. - The project was planned to receive €19.4 million in investments, with an application for European Union funding submitted for its implementation [5]. Current Operations and Future Plans - Despite the postponement, the company continues to implement sustainable organic waste management solutions, transferring poultry manure to farmers and planning to direct part of this waste to a newly built biogas plant in Lukšiai [4]. - AB Akola Group is currently focusing on constructing a biofuel plant in Lukšiai, which is the first project of this scale for the group, with plans for further investments to enhance sustainability and profitability after its completion [3]. Company Overview - AB Akola Group is the largest agricultural and food production group in the Baltic States, employing over 5,000 people and operating along the entire food production chain [6]. - For the first nine months of the 2024/2025 financial year, the consolidated revenue of the group exceeded EUR 1,165 million, reflecting a 3.59% increase compared to the same period in the previous year [6].

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived ...

Core Insights - Fifty1 AI Labs, LLC has announced a strategic partnership with the intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through advanced AI technologies [1][4] - The collaboration will integrate BioSpark's AI and large language model (LLM) platform with Fifty1 AI Labs' predictive modeling to enhance the analysis of extensive medical literature [2][3] Group 1: Partnership and Acquisition - The partnership is designed to leverage AI to extract transformative insights from medical literature, thereby advancing functional medicine and preventative care [1][4] - Fifty1 AI Labs intends to fully acquire BioSpark, which will enhance its capabilities in identifying promising drug repurposing candidates [3][4] Group 2: Technological Integration - BioSpark's proprietary AI platform automates the extraction and structuring of clinical data, which will significantly improve the efficiency of identifying therapeutic patterns [2][3] - The integration of BioSpark's capabilities with Fifty1 AI Labs' Bayesian inference and polypharmacy modeling will create a new approach to drug repurposing based on real-world clinical data [3][4] Group 3: Strategic Vision - The alliance aims to dominate preventative healthcare through personalized, data-driven strategies and rapid identification of drug candidates [4][5] - Both companies share a commitment to enhancing human expertise with ethical AI tools, focusing on opportunities in functional medicine that traditional trials may overlook [5][6] Group 4: Company Background - BioSpark AI Technologies Inc. specializes in organizing real-world clinical data using proprietary AI and LLM technologies and holds a U.S. patent for its automation system [6] - Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., focuses on AI-driven functional medicine, addressing critical needs in performance health and chronic disease prevention [7][8]

Core Viewpoint - Repligen Corporation will report its second quarter 2025 financial results on July 29, 2025, and will host a conference call to discuss these results and business updates [1] Group 1: Financial Reporting - The financial results for the three- and six-month periods ended June 30, 2025, will be discussed during the conference call [1] - A press release will be issued before the market opens on the same day [1] Group 2: Conference Call Details - The conference call can be accessed by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers, with no passcode required [2] - A webcast will also be available via the Investor Relations section of the Company's website, and both the call and webcast will be archived for later access [2] Group 3: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Europe [3]

Core Viewpoint - Johnson & Johnson's Q2 2025 financial results exceeded market expectations, leading to an upward revision of the full-year guidance, driven by strong performance in the MedTech sector, particularly in cardiovascular and wound closure products [1][2][4]. Financial Performance Highlights - Reported sales for Q2 2025 reached $23.743 billion, a 5.8% increase from $22.447 billion in Q2 2024, surpassing market expectations of $22.9 billion [2][3]. - Net earnings for the quarter were $5.537 billion, up 18.2% year-over-year, with diluted EPS at $2.29, reflecting an 18.7% increase [2][3]. - Adjusted net earnings were $6.699 billion, with adjusted EPS at $2.77, slightly above Wall Street's expectation of $2.68 [3]. Full-Year Guidance Revision - The company raised its full-year sales revenue target from $91-91.8 billion to $93.2-93.6 billion, and adjusted EPS expectations from $10.50-10.70 to $10.80-10.90, indicating management's confidence in business momentum for the second half of the year [4]. Market Reaction - Following the earnings report, Johnson & Johnson's stock price rose over 6%, reaching $164.54 per share, reflecting positive investor sentiment due to the strong financial performance and optimistic guidance [5]. MedTech Business Growth Drivers - The MedTech segment reported revenues of $8.541 billion, a 7.3% increase year-over-year, with operational growth at 6.1%. The integration of Shockwave Medical contributed approximately 2 percentage points to this growth [6][7]. - The cardiovascular systems segment showed the most significant growth, with a 23.5% increase driven by electrophysiology devices and Abiomed platform products [7][9]. Surgical Robotics Platform Progress - Johnson & Johnson confirmed that its Ottava surgical robot platform will submit a de novo 510(k) application to the FDA in FY 2026, marking a key milestone in its development [10][14]. - The Ottava platform aims to redefine surgical experiences in the soft tissue robotic market, positioning itself against competitors like Intuitive Surgical's da Vinci system [14]. R&D Pipeline Outlook - The CEO highlighted transformative products in key therapeutic areas, including non-small cell lung cancer and cardiovascular systems, set to enter registration or approval processes [15][16]. - The company maintains a strong commitment to R&D, with Q2 expenses at $3.516 billion, representing 14.8% of total sales, reflecting a stable investment in innovation [16].

TABER, ALBERTA, July 16, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-AMERICAN: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. In addition, FSI is increasing its presense in the food and nutrition supplement manufacturing markets. Today ...